-+ 0.00%
-+ 0.00%
-+ 0.00%

FibroBiologics reports Q3 2026 net loss of $4 million

PUBT·11/16/2026 21:15:59
Listen to the news
FibroBiologics reports Q3 2026 net loss of $4 million
  • FibroBiologics reported a third-quarter 2026 net loss of approximately $4 million.
  • Research and development expenses fell 25% year over year to approximately $2.1 million, while general and administrative costs declined 9% to $2 million.
  • Cash and cash equivalents totaled approximately $1.2 million at September 30, 2026, with subsequent cash infusions totaling approximately $1 million.
  • Initial CYWC628 trial safety data are expected in mid-December 2026, with interim efficacy results anticipated in February 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fibrobiologics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202611161613PR_NEWS_USPR_____DA98106) on November 16, 2026, and is solely responsible for the information contained therein.